1. Standard of care is primary
For many stage I cancers, curative-intent treatment (surgery ± adjuvant therapy as indicated) offers the best evidence-based outcomes. Do not delay biopsy, staging work-up, surgery dates or adjuvant starts because of internet “protocols.”
- Follow the plan agreed with surgical and medical oncology.
- Ask for written stage, grade, biomarkers and follow-up schedule.
- Use second opinions when guidelines leave choices open.
2. Where investigational antiparasitics appear in the conversation
Patients sometimes research ivermectin, fenbendazole or mebendazole after reading lab papers or case reports. At stage I the evidence map is still preclinical, early-phase, or observational — not stage-I-specific approvals.
- MBZ has the strongest formal oncology track (e.g. Johns Hopkins phase I HGG + TMZ; Egypt mCRC combination) — still not a stage I standard.
- IVM appears in combination immuno-oncology trials (e.g. metastatic TNBC NCT05318469; ICONIC NCT07487805) — different disease settings.
- FBZ remains largely preclinical/case-series; no formal human cancer RCT as approved therapy.
3. Process: questions, trials, labs
- Clarify stage and intent — curative vs adjuvant vs surveillance only.
- Search trials — ClinicalTrials.gov filters by condition and country; ask your centre’s trial nurse.
- Disclose all supplements/drugs — including veterinary fenbendazole products — before any planned therapy.
- Discuss labs — LFTs, blood counts and interaction checks if any experimental agent is ever considered under medical care.
4. Published dose ranges (facts only — not orders)
Examples from published oncology contexts (not stage-I prescriptions):
| Context | Published range (study fact) | Source |
|---|---|---|
| MBZ + TMZ, newly diagnosed HGG (phase I) | Dose escalation ~25–200 mg/kg/day under trial monitoring | NCT01729260 / Gallia 2021 |
| MBZ metastatic ACC case (Michigan) | 100 mg twice daily (case report) | PubMed 21454232 |
| MBZ + FOLFOX/bev, mCRC (Egypt) | 500 mg twice daily in study arm | NCT03925662 |
These figures document what studies used. They are not medical orders for stage I self-treatment.
5. Bottom line for stage I
Protocols hub Stage II → Studies
4. Example regimens found in literature / public protocols
Below are cited examples (trials, cases, patient protocols) — not a prescription for you. In stage I: complete curative standard care first.
| Example | Type | Published / discussed regimen | Source |
|---|---|---|---|
| MBZ — Michigan ACC | Case | Mebendazole 100 mg twice daily monotherapy after other therapy stopped; ~19 mo stability in the case | PubMed 21454232 |
| MBZ — Gallia / Hopkins HGG | Phase I | Mebendazole oral dose escalation ~25–200 mg/kg/day with temozolomide; LFTs monitored | NCT01729260 |
| MBZ — Egypt mCRC | Small RCT arm | Mebendazole 500 mg twice daily + FOLFOX4/bevacizumab | NCT03925662 |
| IVM — Cedars-Sinai TNBC | Phase I/II | Ivermectin oral 30 / 45 / 60 mg on days 1–3, 8–10, 15–17 of each 21-day cycle + ICI | NCT05318469 |
| IVM — ICONIC | Phase II | ~200 vs 400 µg/kg ivermectin + checkpoint inhibitor | NCT07487805 |
| FBZ — Tippens-style | Community | Fenbendazole often ~222 mg/day in cyclic schedules + supplements; often concurrent with other cancer therapy | ACS |
| FBZ — veterinary label | Animal label | Panacur C typically 50 mg/kg × 3 days for GI worms — not a human cancer indication | DailyMed |